We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Effects of Anemia Correction on Vascular and Monocyte Function in Renal Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00204334
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : January 13, 2010
Information provided by:
University Hospital Muenster

Brief Summary:

Correction of anaemia in renal transplant recipients by parenteral application of recombinant erythropoietin and if necessary iron will improve large artery function (endothelial function and elasticity), as assessed by ultrasound techniques and applanation tonometry.

The changes in large artery function will be reflected by changes in serological markers of endothelial function and oxidative stress and by changes in monocyte function and apoptosis.

There are gender differences in the responses of vascular function to correction of anemia.

Besides improvement of large artery function, correction of anemia will also affect parameters of graft function, i.e. glomerular and tubular proteinuria.

Condition or disease Intervention/treatment Phase
Kidney Transplantation Anemia Drug: darbopoeitin Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Anemia Correction on Vascular Function, Endothelial Cell Markers and Monocyte Apoptosis in Renal Transplant Recipients
Study Start Date : June 2005
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Vessel wall stiffness

Secondary Outcome Measures :
  1. expression of endothelial cell markers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

kidney transplant recipient stable kidney function Hb between 10mg/ml and 10.5mg/ml

Exclusion Criteria:

acute rejection Hb above 12.0mg/dl

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00204334

Layout table for location information
Münster, NRW, Germany, 48149
Sponsors and Collaborators
University Hospital Muenster
Layout table for investigator information
Principal Investigator: Martin Hausberg, MD UKM- Medical Department D
Layout table for additonal information
Responsible Party: University Hospital Muenster
ClinicalTrials.gov Identifier: NCT00204334    
Other Study ID Numbers: Haus_Lang-Endothel-Mono-Hb
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: January 13, 2010
Last Verified: May 2008
Keywords provided by University Hospital Muenster:
Kidney transplantation
vascular endothelium
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Diseases